Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1992-7-23
|
| pubmed:abstractText |
We have treated sixty-two patients (21 with limited disease, 41 with extensive disease), on an outpatient-basis schedule of six drugs administered weekly for twelve weeks. Cyclophosphamide, 400 mg/m2, adriamycin, 20 mg/m2 and vincristine, 2 mg, full dose, were administered during weeks 1, 5 and 9; cisplatin, 50 mg/m2 and etoposide, 100 mg/m2 during weeks 2, 6 and 10; adriamycin and vincristine at the same doses during weeks 3, 7 and 11; methotrexate 30 mg/m2, during weeks 4, 8 and 12. After the first 28 patients vincristine was replaced by teniposide (VM-26) due to neurotoxicity. The overall response rate was 64.5% (complete remission 13 p., partial remission 27 p.). Toxicity grade 3-4, mainly nausea and vomiting or neutropenia, was recorded in 17 patients. Alopecia grade 1-2 was universal. One toxic death occurred from sepsis. The overall survival was 8 months (range 1-40), (95% CL: 53-77%); 8 months in limited disease (range 1-40), and 7 months in extensive disease (range 1-23). Time to treatment failure was 6 months (7 limited disease, 5 extensive disease). In conclusion, the results of this alternating schedule are poorer than those attained with standard, high-dose treatments, mainly in limited disease, but could be a less toxic option for patients with extensive disease.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0923-7534
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
3
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
31-5
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:1318739-Adult,
pubmed-meshheading:1318739-Aged,
pubmed-meshheading:1318739-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1318739-Carcinoma, Small Cell,
pubmed-meshheading:1318739-Drug Administration Schedule,
pubmed-meshheading:1318739-Drug Evaluation,
pubmed-meshheading:1318739-Humans,
pubmed-meshheading:1318739-Lung Neoplasms,
pubmed-meshheading:1318739-Middle Aged,
pubmed-meshheading:1318739-Prognosis
|
| pubmed:year |
1992
|
| pubmed:articleTitle |
Alternating chemotherapy for small-cell lung cancer. A twelve-week schedule of six drugs.
|
| pubmed:affiliation |
Hospital Clinico, Malaga, Spain.
|
| pubmed:publicationType |
Journal Article
|